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Introduction: Admission blood glucose (BG) level is a predictor of mortality in patients with ST-segment elevation
myocardial infarction (STEMI). However, limited data are available relating admission BG to mortality in patients with
STEMI complicated by cardiogenic shock, and it is not known whether diabetic status has an independent effect on
this relationship.
Methods: Between November 2005 and September 2010, 816 STEMI patients with cardiogenic shock were enrolled
in a nationwide, prospective, multi-center registry; 239 (29.3%) had diabetes mellitus (DM). Patients were
categorized according to BG levels at admission: <7.8, 7.8–10.9, 11.0–16.5 and ≥ 16.6 mmol/L. The primary outcome
was 30-day mortality. The added values of BG to the Thrombolysis in Myocardial Infarction (TIMI) and Global
Registry of Acute Coronary Events (GRACE) scores were assessed by receiver operating characteristic curves and
integrated discrimination improvement analyses.
Results: Thirty-day mortality was higher in patients with higher admission BG (20.4%, 23.3%, 39.8%, and 43.1%
p < 0.001). Among non-diabetic patients, 30-day mortality was predicted by TIMI scores with a c-statistic of 0.615
(95% confidence interval [CI], 0.561–0.662) and GRACE scores with a c-statistic of 0.652 (95% CI, 0.604–0.695).
Incorporation of admission BG increased the c-statistic for TIMI score to 0.685 (95% CI, 0.639–0.720, p < 0.001) and
GRACE score to 0.708 (95% CI 0.664–0.742, p < 0.001). Additional predictive values for BG were not observed for
diabetes. Integrated discrimination improvements (TIMI vs. additional BG and GRACE vs. additional BG) were 0.041
(p < 0.001) and 0.039 (p < 0.001) in non-diabetic patients.
Conclusions: In a cohort of patients with STEMI complicated by cardiogenic shock, admission BG was an
independent predictor of increased risk of mortality only among patients without DM.Introduction
Cardiogenic shock complicating ST-segment elevation
myocardial infarction (STEMI) remains a leading cause
of death with a hospital mortality rate approaching 50%
[1]. The identification of risk predictors of mortality is
important for tailoring more aggressive therapies that can
improve survival in patients with cardiogenic shock [2].* Correspondence: hcgwon@skku.edu
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reproduction in any medium, provided the orAdmission blood glucose (BG) level is an independent
predictor of mortality in patients with STEMI, regardless
of diabetic status and the occurrence of the no-reflow
phenomenon [3-6]. In addition, hyperglycemia is associ-
ated with a higher level of cardiac necrosis markers [7].
Elevated BG level is proposed to be caused by a complex
interplay between counteracting regulatory hormones
such as cortisol, glucagon, growth hormone, and cyto-
kines [8,9]. In heterogeneous populations of critically ill
patients, hyperglycemia is independently associated with
mortality [10,11]. However, limited data are available ford. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Yang et al. Critical Care 2013, 17:R218 Page 2 of 9
http://ccforum.com/content/17/5/R218stratified analysis of the presence or absence of diabetes
mellitus (DM) in patients with cardiogenic shock. We
therefore investigated the impact of admission BG level
on 30-day mortality among patients with STEMI com-
plicated by cardiogenic shock. Furthermore, to improve
the effectiveness of admission BG level as a marker for
short-term mortality, we evaluated the additive predict-
ive value of BG level at admission to the Thrombolysis
in Myocardial Infarction (TIMI) and Global Registry of
Acute Coronary Events (GRACE) risk scores according
to the presence or absence of DM.
Materials and methods
Study population
The study population was selected from the Korea Acute
Myocardial Infarction Registry between November 2005
and December 2007 and from the registry series Korea
Working Group on Myocardial Infarction Registry be-
tween January 2008 and September 2010. Data are from a
prospective multicenter, online registry in Korea, with 53
hospitals registering consecutive patients with acute myo-
cardial infarction. Between November 2005 and Septem-
ber 2010, 20,344 patients were enrolled in the registries.
Data were collected by trained study coordinators using a
standardized case report form and protocol. This registry
was sponsored by the Korean Society of Cardiology. The
institutional review board of all participating centers ap-
proved the study protocol (see Appendix). All participat-
ing patients provided written informed consent. Inclusion
criteria were: consecutive patients 18 years of age or older;
ST-segment elevation of 1 mm or more in two or more
contiguous leads and new left bundle-branch block with atFigure 1 Scheme of group distribution in the registry. KAMIR, Korea Ac
Myocardial Infarction Registry; NSTEMI, non-ST-segment elevation myocardleast one positive cardiac biochemical marker of necrosis;
and diagnosis of cardiogenic shock. Exclusion criteria
were: unavailable BG level at admission; and mechanical
complications such as ventricular septal defect or mitral
regurgitation from myocardial infarction. Patients were
stratified according to BG levels at admission into group 1
(<7.8 mmol/l; n = 181), group 2 (7.8 to 10.9 mmol/l; n =
215), group 3 (11.0 to 16.5 mmol/l; n = 216) or group 4
(≥16.6 mmol/l; n = 204) (Figure 1). Patients with a previ-
ous history of DM treated with insulin, oral antihyper-
glycemic agents, or lifestyle modification at index hospital
admission were classified as patients with DM. The
patient flow of the study is shown in Figure 1. Clinical,
laboratory, and outcome data were collected using a
Web-based reporting system. Additional information
was documented by contacting general practitioners
and by review of hospital records. The primary outcome
was 30-day mortality.
Definitions
A clinical diagnosis of cardiogenic shock was made if all
of the following were present: systolic blood pressure
persistently lower than 90 mmHg or vasopressors re-
quired to maintain a blood pressure greater than 90
mmHg; signs of hypoperfusion (for example, urine out-
put less than 30 ml/hour or cold/diaphoretic extremities
or an altered mental status); and clinical evidence of left
ventricular filling pressure (for example, pulmonary con-
gestion on physical examination or chest X-ray scan).
Vasopressor use was defined as use of dopamine, nor-
epinephrine, and epinephrine regardless of their minimal
dose. Thirty-day mortality was defined as any deathute Myocardial Infarction Registry; KorMI, Korea Working Group on
ial infarction; STEMI, ST-segment elevation myocardial infarction.
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considered to be of cardiac origin unless documentation
indicated another cause. Admission BG was obtained by
arterial or venous samples in an emergency room and
measured with an arterial blood gas analyzer or labora-
tory analyzers in routine use at each hospital.
Calculation of the TIMI and GRACE risk scores
Clinical scoring included the TIMI and GRACE risk
scores for all enrolled patients. Full details of the design
and methods of the TIMI and GRACE risk scores have
been previously published [12,13]. The TIMI risk score
consists of age, prior angina, diabetes, hypertension, systolic
blood pressure <100 mmHg, heart rate >100 beats/minute,
Killip class II to IV, weight <67 kg, anterior ST-segment
elevation or left bundle branch block on electrocardio-
gram, and time to thrombolytics >4 hours. The GRACE
risk score consists of age, heart rate, systolic blood pres-
sure, serum creatinine level at presentation, Killip class,
cardiac arrest at admission, ST-segment deviation on elec-
trocardiogram, and elevated cardiac enzymes. Values for
these variables were entered into the GRACE risk calcula-
tor [14] to obtain estimates of the cumulative risks of all-
cause mortality.
Statistical analysis
All continuous values were presented as the mean with
standard deviation or the median with interquartile
range. Categorical variables were presented as frequen-
cies and percentages. Comparisons between continuous
variables were tested using analysis of variance or the
Kruskal–Wallis test, as appropriate. Categorical data
were tested using the chi-squared test or Fisher’s exact
test, as appropriate. Event-free survival was estimated by
the Kaplan–Meier method and compared using the log-
rank test within 30 days. Covariates statistically signifi-
cant on univariate analysis (P <0.05) and those clinically
relevant were considered candidate variables in multi-
variate models. Cox proportional-hazards models were
adjusted by covariates as follows: age >75 years, sex, body
weight <67 kg, systolic blood pressure (per 10 mmHg
increase), anterior wall infarction on electrocardiog-
raphy, serum creatinine >1.5 mg/dl, mechanical ventila-
tion, intra-aortic balloon pump and admission BG level
(group). Binary logistic regression was employed to
measure the predictive probabilities of the combination
of BG level and established risk score models for 30-day
mortality. Comparisons among the various risk models
of the predictive accuracy with the c-statistic, a measure
of the area under the receiver-operator characteristic
curve, were carried out using the procedure proposed
by DeLong and colleagues according to the presence or
absence of DM [15]. The 95% confidence intervals (CIs)were calculated using the bootstrapping procedure (n =
1,000 bootstrap samples) for area under the receiver-
operator characteristic curve estimations and the diffe-
rences between model areas under the receiver-operator
characteristic curve. Furthermore, we estimated the inte-
grated discrimination improvement to examine whether
predictions based on the TIMI and GRACE risk models
without admission BG level were significantly improved
after inclusion of the admission BG level as a continuous
parameter [16]. Statistical analyses were performed with
SAS 9.2 (SAS Institute Inc., Cary, NC, USA) or Stata ver-
sion 11.0 (StataCorp, College Station, TX, USA). All tests
were two tailed and P <0.05 was considered statistically
significant.Results
Baseline and procedural characteristics
Between November 2005 and September 2010, 844 pa-
tients presented with STEMI complicated by cardiogenic
shock. Of these, 816 (96.7%) had complete admission
BG data (Figure 1). The mean admission BG level was
13.2 ± 7.0 mmol/l. Baseline clinical characteristics are
presented in Table 1; 239 patients (29.3%) were classified
as having DM, including 21 patients treated with insulin.
Overall, patients with higher admission BG levels were
higher-risk subjects. This group had a higher prevalence
of females, DM, low systolic and diastolic blood pres-
sure, anterior wall myocardial infarction, and elevated
serum creatinine and TIMI risk score. Treatment during
hospitalization is shown in Table 2; 644 (78.9%) under-
went primary percutaneous coronary intervention. Simi-
larly, patients with higher admission BG levels had higher
use of mechanical ventilation and intra-aortic balloon
pumps, and were less likely to receive aspirin, clopidogrel,
and statins.Clinical outcomes
Figure 2 shows the cumulative 30-day mortality of the
study population stratified by admission BG level and
presence or absence of diabetes. Total 30-day mortality
was 32.0%; 30-day mortality in patients with diabetes was
36.0% compared with 30.3% for patients without diabetes
(P = 0.115). In the total study population, 30-day mortality
rates were higher in patients with higher admission BG levels
(20.4% for patients with admission BG level <7.8 mmol/l,
23.3% for 7.8 to 10.9 mmol/l, 39.8% for 11.0 to 16.5 mmol/l,
and 43.1% for ≥16.6 mmol/l, P <0.001). Similarly, among
nondiabetic patients, 30-day mortality rates were higher
in patients with higher admission BG levels (20.0%,
22.6%, 40.1%, and 48.9%, P <0.001). However, diabetic
patients showed no significant difference in 30-day mor-
tality according to admission BG level (23.1%, 28.0%,
39.2%, and 38.6%, P = 0.404).
Table 1 Baseline patient characteristics
Serum glucose level on admission
Variable <7.8 mmol/l 7.8 to 10.9 mmol/l 11.0 to 16.5 mmol/l ≥16.6 mmol/l P value
(group 1, n = 181) (group 2, n = 215) (group 3, n = 216) (group 4, n = 204)
Age (years) 67.0 (56.0 to 76.0) 67.0 (56.0 to 76.0) 68.0 (56.0 to 76.0) 67.0 (58.0 to 75.0) 0.804
Sex (male) 126 (69.6) 144 (67.0) 126 (58.3) 117 (57.4) 0.022
Body weight (kg) 61.0 (53.0 to 70.0) 61.0 (55.0 to 69.5) 61.0 (55.0 to 69.3) 61.5 (55.0 to 69.0) 0.766
Diabetes <0.001
Insulin 1 (0.6) 2 (0.9) 8 (3.7) 10 (4.9)
Oral hypoglycemic agent 23 (12.7) 21 (9.8) 52 (24.1) 85 (41.7)
Life style modification 1 (0.6) 2 (0.9) 11 (5.1) 17 (8.3)
Hypertension 82 (45.3) 105 (48.8) 122 (56.5) 108 (52.9) 0.130
Dyslipidemia 51 (28.2) 49 (22.8) 39 (18.1) 39 (19.1) 0.070
Current smoker 88 (26.3) 91 (27.2) 82 (24.5) 74 (22.1) 0.066
Family history of CAD 13 (7.2) 15 (7.0) 16 (7.4) 15 (7.4) 0.998
Previous PCI 9 (5.0) 13 (6.1) 7 (3.2) 8 (3.9) 0.526
Previous CABG 2 (1.1) 1 (0.5) 3 (1.6) 0 0.329
Systolic blood pressure (mmHg) 90 (75 to 120) 80 (70 to 104) 80 (60 to 110) 75 (50 to 100) <0.001
Diastolic blood pressure (mmHg) 60 (50 to 71) 51 (40 to 70) 50 (40 to 70) 50 (34 to 60) <0.001
Heart rate (beats/minute) 74 (55 to 95) 66 (46 to 89) 68 (48 to 100) 68 (37 to 104) 0.116
Infarct location on electrocardiogram
Anterior or LBBB 84 (46.4) 87 (40.5) 112 (51.9) 110 (53.9) 0.027
Inferior 76 (42.0) 113 (52.6) 92 (42.6) 77 (37.7) 0.018
Other 21 (11.6) 15 (7.0) 12 (5.6) 17 (8.3) 0.151
Left ventricular ejection fraction 46.5 (39.0 to 57.0) 47.0 (39.0 to 56.0) 46.0 (36.0 to 57.0) 44.0 (35.0 to 52.5) 0.100
Serum creatinine (mg/dl) 1.1 (0.9 to 1.4) 1.1 (1.0 to 1.4) 1.2 (1.0 to 1.5) 1.3 (1.1 to 1.6) <0.001
TIMI risk score 8 (6 to 10) 8 (6 to 10) 8 (7 to 10) 8 (7 to 10) 0.013
GRACE risk score 227.0 (205.0 to 245.0) 228.0 (208.0 to 248.0) 230.5 (210.0 to 250.3) 230.0 (216.8 to 248.5) 0.227
Values presented as mean ± standard deviation, median (interquartile range) or n (%).
Comparisons between continuous variables were all tested using the Kruskal–Wallis test. CABG, coronary artery bypass grafting; CAD, coronary artery disease;
GRACE, Global Registry of Acute Coronary Events; LBBB, left bundle branch block; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in
Myocardial Infarction.
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without diabetes
Cox regression analysis was performed to determine
predictors of 30-day mortality (Table 3). In nondiabetic
patients, independent predictors for the occurrence of
30-day mortality were female, anterior wall myocardial
infarction, serum creatinine >1.5 mg/dl, mechanical venti-
lation support, use of intra-aortic balloon pump, and
admission BG level group. In diabetic patients, the inde-
pendent predictors for the occurrence of 30-day mortal-
ity were age ≥75 years, female, and low systolic blood
pressure.
Additive prognostic value of admission glucose level to
TIMI and GRACE scores
Receiver operating characteristic curves for admission
BG level, TIMI risk score, GRACE risk score, and the
combination of admission BG and TIMI or GRACEscore are shown in Figure 3. Among nondiabetic pa-
tients, admission BG level and TIMI and GRACE scores
predicted 30-day mortality, with c-statistics of 0.652
(95% CI, 0.600 to 0.691) for admission BG level, 0.615
(95% CI, 0.561 to 0.662) for TIMI score, and 0.652 (95%
CI, 0.604 to 0.695) for GRACE score. The c-statistics
scores increased significantly to 0.685 (95% CI, 0.639 to
0.720, P <0.001) for TIMI and to 0.708 (95% CI 0.664 to
0.742, P <0.001) for GRACE when the admission BG
level was added. Additionally, improvements in discrim-
ination were confirmed by the integrated discrimination
improvement (0.041 (95% CI, 0.022 to 0.059), P <0.001
for TIMI vs. incorporation of BG into TIMI; and 0.039
(95% CI, 0.021 to 0.057), P <0.001 for GRACE vs. in-
corporation of BG into GRACE).
In contrast, in diabetic patients the admission BG level
performed poorly, with a c-statistic of 0.581 (95% CI,
0.513 to 0.651), while the GRACE risk score predicted
Table 2 Treatment during hospitalization
Variable Serum glucose level on admission
<7.8 mmol/l 7.8 to 10.9 mmol/l 11.0 to 16.5 mmol/l ≥16.6 mmol/l P value
(group 1, n = 181) (group 2, n = 215) (group 3, n = 216) (group 4, n = 204)
Primary PCI 138 (76.2) 177 (82.3) 167 (77.3) 162 (79.4) 0.450
Facilitated PCI 6 (3.3) 3 (1.4) 3 (1.4) 2 (1.0) 0.380
Thrombolysis 11 (6.1) 8 (3.7) 9 (4.2) 6 (2.9) 0.470
Medical treatment 26 (14.4) 27 (12.6) 37 (17.1) 34 (16.7) 0.527
Aspirin 175 (96.7) 203 (94.4) 205 (94.9) 177 (86.8) <0.001
Clopidogrel 173 (95.6) 205 (95.3) 200 (92.6) 176 (86.3) 0.001
Low molecular weight heparin 48 (26.5) 56 (26.0) 53 (24.5) 47 (23.0) 0.852
Glycoprotein IIb/IIIa inhibitor 23 (12.7) 32 (14.9) 42 (19.4) 42 (20.6) 0.121
Beta-blockers 96 (53.0) 123 (57.2) 100 (46.3) 104 (51.0) 0.151
ACE inhibitors 92 (50.8) 107 (49.8) 101 (46.8) 95 (46.6) 0.778
Angiotensin receptor blocker 27 (14.9) 31 (14.4) 27 (12.5) 28 (13.7) 0.905
Statins 119 (65.7) 136 (63.3) 118 (54.6) 107 (52.5) 0.016
Mechanical ventilation 48 (26.5) 49 (22.8) 86 (39.8) 85 (41.7) <0.001
Intra-aortic balloon pump 38 (21.0) 46 (21.4) 66 (30.6) 63 (30.9) 0.023
Defibrillator/cardioversion 32 (17.7) 38 (17.7) 46 (21.3) 50 (24.5) 0.257
Temporary pacemaker 22 (12.2) 33 (15.3) 42 (19.4) 40 (19.6) 0.148
Values presented as n (%). ACE, angiotensin converting enzyme; PCI, percutaneous coronary intervention.
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0.720 (95% CI, 0.661 to 0.776) (glucose vs. GRACE, P =
0.011). Performances were not improved by the addition
of admission BG level to TIMI and GRACE risk score
with a nonsignificant increase in the c-statistic of 0.06 for
TIMI (P = 0.585) and 0.08 for GRACE score (P = 0.450).
Furthermore, significant improvements in discrimination
were not observed with the integrated discrimination im-
provement (0.012 (95% CI, 0.003 to 0.027), P = 0.104 for
TIMI vs. incorporation of BG into the TIMI; or 0.014Figure 2 Unadjusted Kaplan–Meier curves. Survival based on admission
with diabetes.(95% CI, 0.002 to 0.031), P = 0.084 for GRACE vs. incorp-
oration of BG into GRACE).
Discussion
We investigated the impact of admission BG level on
30-day mortality and evaluated the additional predictive
value of admission BG to the TIMI and GRACE risk
scores among patients with STEMI complicated by cardio-
genic shock stratified by the presence or absence of DM.
Subjects were enrolled from a nationwide, prospective,glucose level in (A) patients without diabetes and (B) patients
Table 3 Significant predictors of 30-day mortality with and without diabetes
Nondiabetes (n = 577) Diabetes (n = 239)
Variable Hazard ratioa (97.5% CI) Adjusted P value Hazard ratioa (97.5% CI) Adjusted P value
Age ≥75 years 1.10 (0.74 to 1.56) 0.999 1.80 (1.00 to 3.23) 0.049
Sex (female) 1.93 (1.29 to 2.90) <0.001 1.97 (1.07 to 3.62) 0.026
Body weight <67 kg 1.03 (0.67 to 1.60) 0.999 0.76 (0.39 to 1.46) 0.689
Systolic blood pressure, per 10 mmHg increase 0.96 (0.93 to 1.01) 0.108 0.94 (0.87 to 0.99) 0.044
Anterior wall infarction on electrocardiography 1.94 (1.34 to 2.82) <0.001 1.47 (0.85 to 2.57) 0.235
Wide QRS tachycardia on admission 1.55 (0.95 to 2.53) 0.093 1.64 (0.69 to 3.91) 0.406
Serum creatinine >1.5 mg/dl 1.56 (1.09 to 2.25) 0.011 1.61 (0.92 to 2.81) 0.113
Mechanical ventilation 2.36 (1.59 to 3.48) <0.001 1.81 (0.99 to 3.32) 0.056
Intra-aortic balloon pump 1.54 (1.06 to 2.23) 0.019 1.04 (0.57 to 1.87) 0.999
Admission glucose level (vs. group 1)
Group 2 (7.8 to 10.9 mmol/l) 1.19 (0.69 to 2.06) 0.945 2.40 (0.62 to 9.31) 0.296
Group 3 (11.0 to 16.5 mmol/l) 1.76 (1.06 to 2.94) 0.026 1.74 (0.59 to 5.18) 0.507
Group 4 (≥16.6 mmol/l) 1.72 (1.02 to 3.00) 0.030 1.74 (0.60 to 5.04) 0.487
CI, confidence interval.
aAdjusted covariates include age >75 years, sex, body weight <67 kg, systolic blood pressure (per 10 mmHg increase), anterior wall infarction on
electrocardiography, serum creatinine >1.5 mg/dl, mechanical ventilation, intra-aortic balloon pump and admission glucose level (group).
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study were that the 30-day mortality rates were higher in
patients with higher admission BG levels in nondiabetic
patients but not in diabetic patients, and that the admis-
sion BG level had an additional predictive value to TIMI
and GRACE risk score models in nondiabetic patients but
not in diabetic patients.
Acute hyperglycemia on admission and during hospital
stay is associated with adverse outcome in patients with
acute myocardial infarction regardless of diabetic status
[7,9,17,18]. In cardiogenic shock, gluconeogenesis from
acute stress could be more prominent. In our study, the
mean admission BG level (13.2 mmol/l) was consider-
ably higher than a previous study of STEMI patients
with mainly no hemodynamic compromise (7.8 mmol/l).
In patients with STEMI complicated by cardiogenic
shock, our study found that higher BG levels at ad-
mission were associated with higher mortality in the
nondiabetic population but not the diabetic population.
Similarly, a recent study failed to find a significant rela-
tionship between hyperglycemia and mortality in dia-
betic patients with acute myocardial infarction [19]. In
addition, Ishihara and colleagues described a different
relationship between admission BG and in-hospital
mortality in nondiabetic and diabetic patients, and a
hyperglycemia-associated risk that was more obvious in
nondiabetic patients than in patients with diabetes [20].
In a heterogeneous population of critically ill patients,
mean BG is related to ICU mortality in the nondiabetic
cohort but not in the diabetic cohort [21]. These find-
ings suggest that the toxic effect of hyperglycemia on
short-term mortality may be less in known diabeticpatients. One possible explanation is that the definition
and severity of stress hyperglycemia is difficult in dia-
betic patients because they are more likely to receive in-
sulin or oral hypoglycemic agents before admission for
myocardial infarction [22]. These treatments might miti-
gate the toxic effects of stress hyperglycemia and could
disturb the BG level proportionate to the increase in
acute stress in diabetic patients. Another possible ex-
planation is that diabetes patients may develop a resist-
ance to hyperglycemia, and a moderate or severe degree
of hyperglycemia and glycemic variability that might
exert toxicity in a patient without diabetes may be well
tolerated in a patient with diabetes [10].
Identifying high-risk individuals with STEMI compli-
cated by cardiogenic shock remains a challenge. The
most widespread tool is the GRACE risk score, which
was developed from a large unselected population of pa-
tients with all forms of acute coronary syndrome [13].
The TIMI risk score for STEMI is a simple alternative,
derived from patients treated with fibrinolytics [12,23].
Although recent studies suggested variable risk-prediction
models for cardiogenic shock, a robust risk model applic-
able to cardiogenic shock with wide range of mortality
rates has not been developed [24,25]. In our study, incorp-
oration of the admission BG level to the widely accepted
TIMI and GRACE risk scores improved its predictive
values. Moreover, admission BG level alone was compar-
able with the TIMI and GRACE risk scores for short-term
mortality in nondiabetic patients. Accordingly, an addition
of admission BG level to existing risk models could be
helpful for developing a new risk model in cardiogenic
shock and could improve initial bedside risk stratification.
Figure 3 Receiver operating characteristics analysis of predictors of 30-day mortality. Comparison of area under receiver-operating
characteristics curve (AUC) analysis between admission glucose level and the TIMI risk score or GRACE risk score among (A) nondiabetic and
(D) diabetic patients. Comparing the discrimination of the TIMI risk score (B), (E) and the GRACE risk score (C), (F) alone with a model including
admission glucose in predicting 30-day mortality according to the presence of diabetes mellitus. CI, confidence interval; TIMI, Thrombolysis in
Myocardial Infarction; GRACE, Global Registry of Acute Coronary Events.
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known diabetic status on admission. Many STEMI pa-
tients are known to have undetected DM, and they would
not have been excluded in our study [7,17]. Major weak-
ness of this study is the lack of identification data to dis-
tinguish nondiabetes from undetected diabetes. There is
therefore no way to discern differential impact on mortal-
ity between true nondiabetes and undetected diabetes. We
did not routinely measure glycosylated hemoglobin or test
for diabetes during admission. Another limitation might
be that although admission BG will be responsive to the
acute stress associated with a STEMI, many other factors
such as prior meals or diurnal variation can contribute to
the variability of admission BG levels. Association of thehigher admission BG with higher mortality within 30 days
might continue in nondiabetic patients. However, the
mechanism of this finding is unclear. In addition, we could
not identify the impact of BG lowering therapy on mor-
tality because data on BG levels during the course of
hospitalization and therapeutic BG targets were not avail-
able in our registries. The initial treatment strategy on
presentation of a high BG level was left to the operator’s
discretion. Large-scale, randomized trials are needed to in-
vestigate a relationship between BG lowering therapy and
mortality among patients with STEMI complicated by car-
diogenic shock. Lastly, the low 30-day mortality of 32.0%
in our trial might suggest that our investigation included a
relatively high percentage of patients with mild or moderately
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needed mechanical ventilation and 26% underwent inser-
tion of an intra-aortic balloon pump.
Conclusions
In STEMI complicated by cardiogenic shock, the admis-
sion BG level was independently associated with increased
risk of 30-day mortality and had an additional predictive
value for established risk score models in nondiabetic
patients but not in diabetic patients.
Key messages
 In nondiabetic patients with STEMI complicated by
cardiogenic shock, 30-day mortality rates were
higher in patients with higher admission BG levels.
 In diabetic patients with STEMI complicated by
cardiogenic shock, there is no significant difference
in 30-day mortality according to admission BG level.
 In a cohort of patients with STEMI complicated by
cardiogenic shock, the admission BG level had an
additional predictive value to TIMI and GRACE risk
score models in nondiabetic patients but not in
diabetic patients.
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